Introduction Gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma are among the most aggressive malignancies, particularly in their advanced stages. The CheckMate 649 trial previously established nivolumab plus chemotherapy as a superior first-line treatment compared to chemotherapy alone. With five years of follow-up, this latest analysis provides crucial insights into long-term survival, disease progression, and safety outcomes in Chinese patients. Given that nivolumab plus chemotherapy has been approved in over 50 countries as a first-line treatment, this updated evaluation assesses whether its benefits remain sustained over time in this population.
